Inactive Instrument

Strongbridge Biopharma Stock price

Equities

SBBP

IE00BYZ5XL97

Dynamic Chart
Strongbridge Biopharma plc(NasdaqGS:SBBP) dropped from S&P Global BMI Index CI
Strongbridge Biopharma plc(NasdaqGS:SBBP) dropped from S&P TMI Index CI
Strongbridge Biopharma plc(NasdaqGS:SBBP) dropped from NASDAQ Composite Index CI
Xeris Pharmaceuticals, Inc. completed the acquisition of Strongbridge Biopharma plc from HealthCap VI L.P., a fund managed by Odlander, Fredrikson & Co. AB, Caxton Alternative Management LP, and others. CI
Xeris Pharmaceuticals : Shareholders Approve Pending Strongbridge Biopharma Acquisition MT
Strongbridge Biopharma : Says Glass Lewis Recommends Shareholders Vote in Favor of Proposed Deal with Xeris MT
Xeris Pharmaceuticals : ISS Recommends Xeris, Strongbridge Shareholders Vote in Favor of Proposed Deal MT
Strongbridge Biopharma : Earnings Flash (SBBP) STRONGBRIDGE BIOPHARMA Reports Q2 Loss $-0.07, vs. Street Est of $-0.10 MT
Strongbridge Biopharma : Earnings Flash (SBBP) STRONGBRIDGE BIOPHARMA Posts Q2 Revenue $10M, vs. Street Est of $8.89M MT
Strongbridge Biopharma plc Revises KEVEYIS Revenue Guidance for the Full Year 2021 CI
Strongbridge Biopharma plc Announces Publication of Long-Term Efficacy and Safety Results for Keveyis® (Dichlorphenamide) for the Treatment of Primary Periodic Paralysis in Muscle & Nerve CI
Insider Trends: Insider at Strongbridge Biopharma Makes Tax Sale Extends 90-Day Selling Trend MT
Strongbridge Biopharma plc(NasdaqGS:SBBP) dropped from Russell 2000 Value Index CI
Strongbridge Biopharma plc(NasdaqGS:SBBP) dropped from Russell 2000 Growth Index CI
Strongbridge Biopharma plc(NasdaqGS:SBBP) dropped from Russell Small Cap Comp Value Index CI
More news
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing's syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).
Sector
-
More about the company
  1. Stock
  2. Equities
  3. Stock Strongbridge Biopharma - Nasdaq